Last reviewed · How we verify
NCT06903130
Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) Levels in Patients With Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD)
trial testing Blood samples for sNfL and sGFAP levels in NMOSD in 40 participants. Not yet recruiting.
1 September 2027
Quick facts
| Lead sponsor | National and Kapodistrian University of Athens |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 September 2025 |
| Primary completion | 1 September 2027 |
| Estimated completion | 1 June 2028 |
| Sites | 1 location across Greece |
Drugs / interventions tested
- Blood samples for sNfL and sGFAP levels
Conditions studied
- NMOSD — all drugs for NMOSD →
Sponsor
National and Kapodistrian University of Athens
Who can join
18 and older, any sex, with NMOSD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a nationwide observational study looking at how ravulizumab, a complement C5 inhibitor, affects blood biomarkers o sNfL and sGFAP in people with AQP4-antibody positive NMOSD. The study does not change your treatment-only regular blood samples are collected to monitor these markers
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06903130
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for NMOSD
Currently open trials in the same condition.
- NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting
- NCT07087873 — Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiop · NA · recruiting
- NCT06724809 — Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD · Phase 3 · active not recruiting
- NCT06775912 — Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases · EARLY_PHASE1 · recruiting
- NCT05966467 — Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies · recruiting
Other National and Kapodistrian University of Athens trials
Trials by the same sponsor.
- NCT07295964 — Accuracy of Intraoral Scan Post-processing Methods: A Clinical Trial · NA · not yet recruiting
- NCT07351981 — TcPRF for Knee Osteoarthritis · NA · enrolling by invitation
- NCT07477496 — Recurrence and Anal Fistula Patient Reported Outcomes Trial · recruiting
- NCT07295899 — Assessing the Influence of Implant Scanning Techniques on the Accuracy of Maxillary Complete-Arch Digital Scans for Impl · not yet recruiting
- NCT07077122 — Evaluation of the Systemic Burden of Non-surgical Periodontal Therapy: A Randomized Clinical Trial on Five Different Tre · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06903130 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National and Kapodistrian University of Athens
- Last refreshed: 1 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06903130.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing